Yaghoobi, Vesal
Moutafi, Myrto
Aung, Thazin Nwe
Pelekanou, Vasiliki
Yaghoubi, Sanam
Blenman, Kim
Ibrahim, Eiman
Vathiotis, Ioannis A.
Shafi, Saba
Sharma, Anup
O’Meara, Tess
Fernandez, Aileen I.
Pusztai, Lajos
Rimm, David L. http://orcid.org/0000-0001-5820-4397
Funding for this research was provided by:
national cancer institute (R01-CA219647)
Article History
Received: 20 June 2021
Accepted: 1 December 2021
First Online: 14 December 2021
Declarations
:
: The study was approved by the Yale Human Investigation Committee protocol #9505008219 and conducted in accordance with the Declaration of Helsinki. All patient tissue was collected on the basis of the approved protocol where there was patient consent or waiver of consent in some appropriate circumstances.
: Not applicable.
: David L. Rimm has served as an advisor for Astra Zeneca, Agendia, Amgen, BMS, Cell Signaling Technology, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, GSK, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana and Ultivue. Amgen, Cepheid, NavigateBP, NextCure, and Konica Minolta fund research in David L. Rimm’s lab. L.P. has received consulting fees and honoraria from Pfizer, Astra Zeneca, Merck, Novartis, Bristol-Myers Squibb, Pfizer, Genentech, Eisai, Pieris, Immunomedics, Clovis, Syndax, H3Bio, Radius Health, Daiichi, and institutional research funding from Seagen, AstraZeneca, Merck, Pfizer and Bristol Myers Squibb. Kim RM Blenman is on the scientific advisory board of CDL Labs.V.P is currently employee of Sanofi US. Other authors have no potential conflict of interest.